CLINICAL TRIAL / NCT05519449

Inclusion Criteria: - Male ≥18 years of age at the time of signing informed consent - Histologically or cytologically confirmed adenocarcinoma of the prostate - Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible - Adequate organ function Exclusion Criteria: - Prior solid organ transplant - Prior treatment with PSMA-targeted CAR-T cell therapy or PSMA-CD3, PSMA-CD28 or other CD3 T-cell engaging bispecific antibodies - Clinically significant cardiovascular disease - Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other) - Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment